Hepatitis B is able to be converted in a small percentage of patients with interferon. Hepatitis B is caused by hepatitis B virus infection, the current new guidelines put forward the concept of clinical cure, that is, select some advantageous people in the treatment to achieve hepatitis B surface antigen conversion. At present, treatment with interferon alone or interferon combined with antiviral drugs together, some patients can make the surface antigen turn negative, can achieve the effect of clinical cure. However, the probability of interferon surface antigen conversion is still not high, which is related to the type of population and the degree of viral replication. Generally speaking, the probability of interferon conversion is relatively high if the patients are female, young, have no family history of hepatitis B, have low or medium level of hepatitis B virus replication, and have low hepatitis B surface antigen.